Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 4, 2010, Pages 285-289

  Parikh, Sameer A ^a   Kantarjian, Hagop ^a   Schimmer, Aaron ^b   Walsh, William ^c   Asatiani, Ekatherine ^d   El Shami, Khaled ^d   Winton, Elliott ^e   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Ataxia; Polycythemia vera; Post essential thrombocythemia myelofibrosis; Targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; HEMOGLOBIN; OBATOCLAX; PROTEIN BCL 2;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; PHASE 2 CLINICAL TRIAL; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; BLAST CELL CRISIS; CHILL; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DYSPNEA; EUPHORIA; FEVER; FOLLOW UP; HEADACHE; INSOMNIA; METABOLIC ACIDOSIS; MOLECULARLY TARGETED THERAPY; NAUSEA; OPEN STUDY; OUTPATIENT CARE; PATIENT COMPLIANCE; PNEUMONIA; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TUMOR CELL DESTRUCTION;

EID: 77957029255     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.059     Document Type: Article

References (29)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342:1255-65.
2. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59:171-91.
3. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008; 22:474-86.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-8. (Pubitemid 40663494)
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90. (Pubitemid 40570926)
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-97.
8. Kerr IM, Costa-Pereira AP, Lillemeier BF, et al. Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett 2003; 546:1-5.
9. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003; 14:1448-59.
10. Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in stat5a-/-5b-/-mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98:181-91.
11. Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338:564-71.
12. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104:19512-7.
13. Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68:3413-20.
14. Trudel S, Li ZH, Rauw J, et al. Preclinical studies of the pan-Bcl inhibitor obato-clax (GX015-070) in multiple myeloma. Blood 2007; 109:5430-8.
15. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:8295-301.
16. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108:1497-503.
17. Offen D, Beart PM, Cheung NS, et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 1998; 95:5789-94.
18. Tamatani M, Ogawa S, Nunez G, et al. Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ 1998; 5:911-9.
19. Hickman JA, Hardwick JM, Kaczmarek LK, et al. Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission. J Neurophysiol 2008; 99:1515-22.
20. Raza A, Galili N, Borthakur G, et al. A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol 2009; 27(15 suppl):165s (abstract 3579).
21. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113:299-305.
22. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-32.
23. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24:4738-45.
24. O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27:5208-12.
25. Mesa RA, Verstovsek S, Rivera C, et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 2008; 22:1636-8.
26. Mesa RA, Verstovsek S, Rivera C, et al. 5-azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009; 23:180-2.
27. Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22:740-7.
28. Giles FJ, List AF, Carroll M, et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res 2007; 31:891-7.
29. Giles FJ, Cooper MA, Silverman L, et al. Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer 2003; 97:1920-8.